Integrated Chinese and western medicine interventions for atopic dermatitis: a systematic review and meta-analysis

Chi Him Sum1, Jessica Ching1,2, Hongwei Zhang1,2, Steven Loo2, Cho Wing Lo1, Mei Kwan Lai1, Pui Kuan Cheong1, Chau Leung Yu1 and Zhi-xiu Lin1,2*

Abstract

Background: Atopic dermatitis (AD) is a chronic relapsing skin disease characterized by recurring episodes of itchiness with skin erythema and surface damages. Chinese medicine (CM) is widely used for the management of AD in China not only by its own, but also used in combination with conventional therapy (integrated Chinese-Western medicine, ICWM). Although many clinical trials on the effectiveness of ICWM on AD have been conducted, however, up to date, no sound evidence has been established on the clinical effectiveness and safety of ICWM for AD.

Objectives: To systematically review the currently available clinical evidence on the clinical effectiveness and safety of ICWM for AD.

Methods: Randomised and quasi-randomised controlled trials, which investigated ICWM interventions with at least one control group using the same conventional interventions, no treatment or placebo treatment, were included. Four English (CENTRAL, MEDLINE, EMBASE, AMED) and three Chinese (CNKI, CBM, WanFang Med) databases were searched. Risk of bias was assessed according to the Cochrane's tool. Meta-analysis was performed to pool the data.

Results: From 1473 entries, 55 studies were included, involving 5953 participants aged between 35 days and 67 years old. Duration of treatment ranged from 1 to 24 weeks. Only 2 studies were judged to have low risk of bias, 3 studies had unclear risk of bias, and the other 50 studies were with high risk of bias. ICWM was found to be superior over WM alone in improving clinical severity of AD (measured by EASI, SCORAD), health-related quality of life (measured by CDLQI, DLQI), long term control of AD (recurrence rate), patients/investigator global score (clinical effectiveness rate), and serum IgE level. Adverse events associated with ICWM were found to be comparable with WM alone.

Conclusion: ICWM seems to produce superior treatment response than WM alone in managing AD without increased risk of adverse events. However, the current available evidence remains too weak to make a conclusive decision.

Keywords: Atopic dermatitis, Integrated Chinese-Western medicine, Chinese medicine, Systematic review, Meta-analysis
most significant clinical symptoms. It affects around 15% to 30% of children and 2% to 10% of adults worldwide [3, 4]. In Hong Kong, the incidence rate of AD was 15% to 20% of the general population [5].

The pathogenesis of AD involves interactions among genetic and environmental factors, skin barrier dysfunction, microbial imbalance and immune dysregulation [6–8]. Multiple factors are believed to underlie dysfunctional T-helper (Th) cell type 1, Th2, and Th17 innate and adaptive immune responses in patients with AD [7, 8]. Currently anti-inflammatory treatment with topical corticosteroids and/or topical calcineurin inhibitors is widely used for the management of mild to moderate form of AD, while systemic immunosuppressive agents, such as glucocorticoids, cyclosporine, or methotrexate, can be used in severe cases [8, 9]. Long-term topical corticosteroid use is associated with side effects including stretch marks, small red or purple spots, telangiectasia (small, dilated blood vessels on the surface of the skin), skin thinning, atrophy and acne. Topical use of excessive corticosteroids can also cause hypothalamic-pituitary axis suppression [1, 6]. The systemic immunosuppressive agents do not target specific points of immune dysregulation in AD, and may result in severe adverse events, including liver and kidney impairment. Ultraviolet phototherapy can be used for generalized AD, but it is contraindicated in children and young adults because of its long-term use is associated with the occurrence of skin cancer.

Complementary and alternative medicine has been increasingly used for the management of AD worldwide [10]. Chinese medicine (CM) is nowadays widely used for treating AD in East Asia and provides a valuable alternative treatment option. Many clinical studies have been conducted to evaluate the effectiveness of Chinese herbal medicines (CHMs) for the treatment of AD in recent decades [11, 12]. Findings suggested that oral use of CHMs may improve health-related quality of life for children with moderate or severe atopic eczema. As integrated Chinese and Western medicine (ICWM) is a common way of clinical practice in mainland China, many clinical studies have been published on the effectiveness of ICWM on AD [13]. However, currently no solid evidence is available to support the effectiveness and safety of ICWM for AD treatment.

Since 1997, the Hong Kong Special Administrative Region Government has adopted an evidence-based approach in promoting the use of ICWM. High quality evidence on the use of ICWM is in urgent need. We would therefore like to fill in the gap by conducting a systematic review focusing on the use of ICWM for AD. The evidence synthesized would likely help develop a pragmatic collaborative care model for both WM and CM practitioners for the management of AD in Hong Kong.

Methods

Eligibility criteria

We included randomised controlled trials (RCTs) or quasi-RCTs using a superiority design, which evaluated the use of investigated WM & CM interventions or its variants on the patients with atopic dermatitis. The herbal medicines included single herb, classical formulae, new formulae, herb-derived products and combination products. The control group should receive the same WM interventions, no treatment or placebo. The WM medicine included both oral and topical application of chemical drugs such as antihistamines, corticosteroids and other modalities such as UV light therapy.

Studies on “chronic eczema”, “subacute eczema” and “acute eczema” were generally excluded, except when they use a recognized diagnosis of AD such as the Hanifin and Rajka’s criteria or the UK working group criteria explicitly [14]. Studies on other types of eczema such as anal eczema, genital eczema, dyshidrosis, eczema rhagadiforme, keratinized eczema were all excluded. Trials with co-morbidity other than allergy-related diseases (e.g. asthma) were also excluded.

The included studies should report one or more of the following primary and secondary outcomes. The primary outcome was the clinical severity of eczema, measured by a validated or objective tool, such as eczema area and severity index (EASI), scoring atopic dermatitis (SCORAD), six area, six sign atopic dermatitis (SASSAD) severity score, investigators’ global assessment (IGA), and affected body surface area (BSA). The secondary outcomes included participant-reported symptoms, health-related quality of life, long-term control of atopic dermatitis (defined as the status of disease control at least 1 week after the end of intervention, such as recurrence rate), serum IgE level and adverse events. The percentage of trial participants with more than 50% improvement in terms of patients or investigator global score (“clinical effectiveness rate”, further explained in “Results” section) was also accepted as one of secondary outcomes as it is widely used in the studies conducted in China based on national guidelines.

Participant-reported symptoms should be measured by a validated tool, such as patient-oriented eczema measure (POEM) and Pruritus Visual Analogue Scale (pruritus VAS). Health-related quality of life should also be measured by a validated measure, such as Dermatology Life Quality Index (DLQI) and Children’s Dermatology Life Quality Index (CDLQI).
Search strategy
Literature search strategies were developed using medical subject headings and text words related to eczema. Various synonyms of the concepts of “eczema”, “Chinese medicine”, “integrative medicine” and “randomised controlled trials” were combined by “And” to construct the searching strategies. We searched the Cochrane Central Register of Controlled Trials (CENTRAL, via Cochrane Library, searched on 16 Oct 2019), MEDLINE (via Ovid, 1948 to 16 Oct 2019), EMBASE (via Ovid, 1974 to 16 Oct 2019) and AMED (via Ovid, 1985 to 16 Oct 2019). We also searched the main Chinese databases including the China National Knowledge Infrastructure (CNKI, 1915 to 18 Oct 2019), the Chinese BioMedical Literature Database (CBM, via SinoMed, 1978 to 18 Oct 2019) and Wanfang Med Online (For dissertations and conference proceedings only, 1998 to 18 Oct 2019).

Previous systematic reviews or meta-analyses on AD were also examined to identify potential trials eligible to be included.

Data extraction
The systematic review was conducted and reported according to the Cochrane Handbook for Systematic Review of Interventions (version 5.1) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [15, 16].

All titles and abstract of the entries returned by the search were imported into Covidence, an online collaboration tool designed to facilitate the work in different stages in systematic reviews, to remove duplicates and enable online screening. A review author (SCH) independently screened all the titles and abstracts against the original inclusion and exclusion criteria, and obtained full-texts of all entries that matched the inclusion criteria. Each of four reviewers (SCH, LMK, LCW, CPK) then screened part of the obtained full text articles and extracted characteristics of the studies. Another reviewer (LCW) rescreened the titles and abstracts classified as irrelevant to ensure completeness of inclusion, and a reviewer (SCH) rescreened the articles that did not explicitly describe atopic dermatitis (e.g. those articles that used “acute eczema”, “subacute eczema” or “chronic eczema”) to check whether AD's criteria were actually used for those studies. All questionable cases were referred to another reviewer (LZX) for decision. The final list of included articles was then determined. We resolved disagreement through discussion, and recorded the reasons for excluding articles/studies. The review authors were not kept blind to the journal titles or to the study authors or institutions.

One review author (SCH) extracted outcome data in the included studies and input them onto an excel spreadsheet. The means, standard deviations of continuous outcomes and the numbers of events of dichotomous outcomes were recorded. Other information including age, diagnosis, type of intervention (including constituent component and dose), randomisation method, sample size, primary and secondary outcome types were also recorded.

Risk of bias assessment
Two review authors (SCH and LCW) independently assessed potential risks of bias in all included studies using the Cochrane's tool for assessing the risk of bias [15]. They assessed all six domains (sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias) in each study and assigned a scale of high, low, or unclear risk of bias. The discrepancy in judgment was resolved by another author (ZHW).

Data synthesis and statistical analysis
We used risk ratio (RR) with 95% confidence intervals (CI) to summarize dichotomous outcome data of individual studies, and used Mantel–Haenszel random-effects model to pool the results across studies. We used the mean difference (MD) with 95% CI to summarize continuous outcome data at the end of treatment or follow-up within studies, and used the inverse-variance random-effects model to pool the results. For meta-analysis, we used random-effects model because of the expected heterogeneity of the studies. RevMan 5.1 software was used for data analyses. Forest plots were made to assess the effect size and corresponding 95% CI using random-effects models. Heterogeneity was assessed using the $I^2$ test with the significance level set at $I^2 > 50\%$ or $P < 0.1$.

We planned to perform subgroup analyses based on patients’ age (less or more than 12); however, this was eventually found to be infeasible as the majority of included studies (31 out of 56) contained patients of both age groups. We assessed the possibility of publication bias by using funnel plots when at least 10 studies reported the outcomes. Sensitivity analyses were performed to evaluate the influence of study methodological quality and that of using change from baseline data (with missing standard deviation imputed) instead of post-intervention data, when the imputation of standard deviation could be made based on available data.
Results

Study selection

The electronic database search returned 1473 records. A total of 998 records remained after duplicates were removed. After the title and abstract screening, 650 irrelevant records were excluded and 348 full-text records were assessed for eligibility. And 6 additional records were identified from previous systematic reviews and trial summaries. Eventually, a total of 55 trials (in 61 search records [17–77]) were included. (Fig. 1, flow of study selection).

Study characteristics

All 55 included studies were randomised controlled trials (RCTs). Among them, 5 studies were published in English and the remaining ones in Chinese. The included studies involved 5953 participants. The age of participants ranged from 35 days to 67 years old. Around 64% of the included studies (35 out of 55, involving 2987 participants) explicitly excluded patients who had received certain western medicine treatment (systemic corticosteroids: 35 studies, 2987 participants; immunosuppressants: 19 studies, 1680 participants; topical corticosteroids: 18 studies, 1256 participants; immunomodulators: 17 studies, 1577 participants; antihistamines: 16 studies, 1273 participants; antibiotics: 9 studies, 588 participants; phototherapy: 6 studies, 479 participants) within certain period (7 days to 2 months before screening) from participating in the trials.

All the included trials compared the use of Chinese herbal medicine combined with Western medicine to the use of same Western medicine alone (baseline treatment). CHMs included oral and topical use of Chinese herbal medicine in the form of decoction, granules or proprietary Chinese medicine (pCM).

Western medicine treatment included oral and topical medicines (such as emollients, antihistamines, topical corticosteroids, topical calcineurin inhibitors, urea-containing cream, antibiotics, anti-septic solutions, vitamin C or non-pharmacological therapy such as UV light therapy). The duration of treatment ranged from 1 to 24 weeks.

For primary outcomes, the included studies reported EASI, SCORAD, SASSAD, IGA (Clinical severity of eczema), POEM and pruritus VAS (Participant-reported symptoms). The most commonly reported (count ≥ 5) primary and secondary outcomes among the selected domains were clinical effectiveness rate (49 RCTs), SCORAD (20 RCTs), recurrence rate (16 RCTs), IgE level (12 RCTs), EASI (8 RCTs), and pruritus relief in Visual Analogue Scale (5 RCTs).

Chinese medicine syndromes and Chinese herbal medicines

Twenty-seven studies mentioned some types of Chinese medicine syndrome 證候, and totally 15 syndromes were identified in those studies (Table 1). The four most common syndrome types were damp-heat 湿熱 (566
participants), spleen deficiency with dampness accumulation (脾虚湿蕴 377 participants), spleen deficiency (脾虚 309 participants) and blood deficiency and wind-dryness (血虚风燥 304 participants).

From the Chinese medicine perspective, the herbs used in the formulae generally have at least one of the following functions:

1. Fortifying the spleen and replenishing qi (健脾益气) [e.g. Atractylodis Macrocephalae Rhizoma (Baizhu, 白术), Pseudostellariae Radix (Taizishen, 太子参)];
2. Inducing diuresis to drain dampness (利水渗湿) [e.g. Coicis Semen (Yiyiren, 薏苡仁), Poria (Fuling, 茯苓)];
3. Clearing heat and drying dampness (清热燥湿) [e.g. Phellodendri Chinensis Cortex (Huangbai, 黄柏), Scutellariae Radix (Huangqin, 黄芩)];
4. Dispersing wind and discharging heat (祛風泄熱) [e.g. Forsythiae Fructus (Lianqiao, 连翘), Dictamni Cortex (Baixianpi, 白鲜皮)];
5. Clearing heat to cool the blood (清热凉血) [e.g. Moutan Cortex (Mudanpi, 牡丹皮), Scrophulariae Radix (Xuanshen, 玄参)];
6. Tonifying blood (养血) [e.g. Angelicae Sinensis Radix (Danggui, 当归), Paeoniae Radix Alba (Baishao, 白芍)];
7. Nourishing yin (滋阴) [e.g. Ophiopogonis Radix (Maidon, 麦冬), (Asparagi Radix (Tiandong, 天冬));
8. Invigorating blood (活血) [e.g. Chuanxiong Rhizoma (Chuanxiong, 川芎), Persicae Semen (Taoren, 桃仁)].

The frequency of usage, functions and classifications of the top 20 most frequently used CHMs in the included studies were summarised in Table 2. These 20 CHMs can be classified into 11 categories according to their main functions in Chinese medicine. They are, in descending order of their prescribing frequency: qi-tonifying, heat-clearing and dampness-drying, water-draining and swelling-dispersing, heat-clearing (清热), blood-tonifying (补血), heat-clearing and blood-cooling (清热凉血), stranguria-relieving diuretics (利尿), qi-regulating (理气), liver-pacifying (平肝), and heat-clearing and detoxicating (清热解毒). These match well with the pathophysiology of AD in CM theory, i.e. accumulating dampness, heat and wind and the associated spleen qi deficiency that could result in blood deficiency if it persists into the chronic stage.

A total of 42 herbal formulae with specific names were identified in the included studies. The most commonly used formulae was Danggui Yinzi (当归饮子), a blood tonifying and wind dispersing (补血祛风) formula designed to resolve blood deficiency and wind-dryness (血虚风燥, which is a common CM syndrome in the chronic stage of AD), with 4 studies using it as the main intervention.

**Table 1** CM syndromes identified in the included studies

| CM syndromes in Chinese | English translation | No. of participants |
|-------------------------|--------------------|--------------------|
| 湿热                    | Damp-heat          | 566                |
| 脾虚湿蕴                | Spleen deficiency with dampness accumulation | 377                |
| 脾虚                    | Spleen deficiency  | 309                |
| 血虚风燥                | Blood deficiency and wind-dryness | 304                |
| 风湿热                  | Wind-damp-heat     | 104                |
| 脾肾虚寒                | Spleen and kidney yang deficiency | 97                 |
| 脾虚风燥                | Spleen deficiency with wind-dryness | 90                 |
| 风温热湿                | Wind-dampness accumulation in skin | 72                 |
| 心火偏盛                | Hyperactive heart fire | 60                |
| 湿滞                    | Dampness stagnation | 60                 |
| 脾虚血燥                | Spleen deficiency accompanied with yin deficiency | 60                |
| 陰虚火燥                | Spleen deficiency with heart fire | 47                 |
| 陰虚风燥                | Spleen deficiency with blood dryness | 47                 |
| 脉凝                    | Fetal heat         | 40                 |
| 陰虚血燥                | Yin deficiency with blood dryness | 40                 |

**Risk of bias within studies**

About a third of included studies described an appropriate way of generating a random sequence (e.g. generation by computer software, coin tossing, random number table) and deemed to have low risk of bias in the domain of random sequence generation. Only 3 studies described
The allocation concealment method, and deemed to have low risk of bias in this domain [17–19]. Five studies took measures to blind participants, study personnel and outcome assessors [17–21]. Most of the studies (47 out of 55) had low risk of bias in incomplete outcome data. Most of the studies (53 out of 55) had unclear risk of bias in selective reporting because no relevant information was available. Overall, 2 studies [17, 18] were judged to have low risk of bias, 3 studies [19–21] had unclear risk of bias, and the other 50 studies had high risk of bias. Figure 2 shows the risk of bias graphs and summaries.

**Effects of interventions**

**Primary outcomes**

Thirty-three studies measured clinical severity of atopic dermatitis by validated measurement scales. Among these, 18 [22, 24–29, 31, 32, 37–40, 42, 51, 54, 56, 57, 60, 68, 69] used SCORAD and 8 [17, 20, 34, 46, 55, 63, 70, 75] used EASI. Seventeen studies [22, 25–29, 31, 32, 37–40, 42, 51, 54, 56, 57, 60, 68, 69] used SCORAD and 5 [17, 34, 55, 70, 75] using EASI were included in meta-analysis because of data availability. In both measures, ICWM was superior to WM alone (SCORAD: MD = −11.06, 95% CI −16.53 to −5.60, participants = 1961, I² = 99%, Fig. 3a, effects of ICWM on the clinical severity of AD measured by SCORAD when compared with WM alone; EASI: MD = −2.68, 95% CI −4.95 to −0.42, participants = 371, I² = 94%, Fig. 3b, effects of ICWM on the clinical severity of AD measured by EASI when compared with WM alone). High heterogeneity was evidenced and possibly due to the varied interventions in these studies.

Furthermore, sensitivity analysis was conducted to examine the influence of study quality (including only study of low risk of bias) and that of using the change of score from the baseline rather than post-intervention scores as the outcome. The only study of low risk of bias [17] reported no significant difference between the ICWM and WM alone groups in the term of EASI change. When the change of score from baseline was used, with the missing SD of EASI imputed from figures reported in Gu et al. [17] and that of SCORAD imputed from Chen et al. [22], ICWM was still superior to WM alone (SCORAD: MD = −8.15, 95% CI −12.89 to −3.41; EASI: MD = −2.59, 95% CI −4.48 to −0.70).

Other measures included IGA [20], SASSAD [35, 36], Skin Severity Score by Japanese Dermatological Association [18] and 3 different kinds of author-defined clinical lesion/symptom scores [19, 33, 64]. Except for the
Japanese study applying IGA, which showed no significant difference between ICWM and WM groups in terms of IGA (with the amount of topical agents used in the WM group substantial higher than in ICWM group), all other studies indicated that ICWM was superior to WM in their respective measures.

Secondary outcomes

Participant-reported symptoms Six studies measured participant-reported symptoms by validated measurement scales. Among these, 5 used pruritus visual analogue scale (VAS) [20, 27, 28, 39, 46], of which 3 were included in the meta-analysis [27, 28, 39]. The result of meta-analysis showed no significant difference between the ICWM and
WM alone groups (MD = −1.21, 95% CI = −2.45 to 0.02, participants = 203, I² = 96%). Only 1 study [17] measured participant-reported symptoms by POEM, and no significant difference was found between two groups.

Health-related quality of life Seven studies measured health-related quality of life by validated measure scales. Among these, 3 used only CDLQI [17, 24, 55], 3 used only DLQI [23, 54, 70], and one used a score combined from both CDLQI and DLQI [31]. Two studies using only CDLQI [17, 55] and 3 studies using only DLQI were included in the meta-analysis. The study with combined score was not included for the meta-analysis as the scores were combined in an unspecified way and not separately available. In both measures, ICWM was superior to WM alone (CDLQI: MD = −2.12, 95% CI = −3.93 to −0.31, participants = 125, I² = 1%; DLQI: MD = −3.12, 95% CI = −5.03 to −1.22, participants = 206, I² = 94%). However, sensitivity analysis showed no significant difference between groups in terms of CDLQI (MD = −1.41, 95% CI
Long-term control of atopic dermatitis (defined as the status of disease control at least 1 week after the end of intervention) Sixteen studies measured long-term control of AD [31–33, 39, 41, 47, 50, 51, 55, 58, 60, 63, 67, 69, 70, 75]. All were expressed in some forms of “cases of recurrence” or “recurrence rate” with observing intervals from 1 week to 1 year. The pooled analysis of 16 studies showed that ICWM was superior to WM alone in reducing recurrence rate (RR = 0.47, 95% CI 0.38 to 0.58, participants = 1246, I² = 0%).

Percentage of trial participants with more than 50% improvement in terms of patients or investigator global scores (clinical effectiveness rate) Most included studies in Chinese (49 out of 50) reported a set of ordinal percentage measures, such as no effect rate, effective rate, significantly effective rate, or complete recovery rate, which were based on different patient’s or investigator’s global scores, either validated (like EASI, SCORAD or SASSAD) or self-defined. For each study, we grouped subjects with more than 50% improvement in terms of global scores into one category, and those lower than 50% were grouped into another. Percentages of the former categories over the total sample sizes were defined as “clinical effectiveness rates” in this review, and meta-analyzed as a dichotomous outcome.

There were 4, 15, 5 and 24 studies which adopted EASI [55, 58, 70, 75], SCORAD [13, 22, 28, 29, 31, 32, 37, 38, 40, 42, 51, 54, 56, 60, 68, 69], SASSAD [30, 36, 52, 61, 62] and other measures [23, 25, 27, 33, 34, 39, 41, 44–50, 53, 59, 62, 64–67, 71, 72, 74], respectively, as their basis for calculating the percentages. Meta-analyses were performed separately for these four groups. All four groups with different measures showed that ICWM was superior to WM alone in improving clinical effectiveness rate (EASI: RR = 1.30, 95% CI 1.13 to 1.51, participants = 307, I² = 0%, Fig. 4a; SCORAD: RR = 1.46, 95% CI 1.24 to 1.72, participants = 1547, I² = 72%, Fig. 4b; SASSAD: RR = 2.50, 95% CI 1.79 to 3.49, participants = 311, I² = 0%, Fig. 4c; all other measures: RR = 1.35, 95% CI 1.23 to 1.49, participants = 2831, I² = 77%, Fig. 4d). The high heterogeneity in the SCORAD and other measurement groups was probably due to the diverse range of interventions involved.

Apart from the above, one English study [18] reported “prominent efficacy rate” (defined as the rate of subject with skin severity scoring 0 at the end of study). The difference between ICWM and WM alone groups was not significant (ICWM: 19%, 7 of 37; WM alone: 5%, 2 of 40; P = 0.06).

Serum IgE level Twelve studies [19, 21, 24, 26, 30, 33, 40, 53, 58, 62, 64, 71] measured serum IgE level. Among them, 10 studies [21, 26, 30, 33, 40, 53, 58, 62, 64, 71] were included in the meta-analysis. Pooled analysis showed that ICWM was superior to WM alone in attenuating IgE level (MD = −48.53 kU/L, 95% CI −79.67 to −17.38, participants = 884, I² = 80%). The high heterogeneity was possibly due to the different interventions involved. For sensitivity analysis, if change from baseline data was used instead of post-intervention data, with missing SD imputed from figures report in the study Zhou et al. [64], ICWM would still be superior to WM alone in attenuating IgE level (MD = −45.69 kU/L, 95% CI −84.1 to −7.29).

Funnel plots were made for the outcomes that have at least 10 studies included in the meta-analysis. The pooled data on SCORAD, the percentages of trial participants with more than 50% improvement in terms of SCORAD or “other measures” as defined above, and serum IgE level were examined by funnel plots. Apart from the one with SCORAD, the plots were all highly asymmetrical, suggesting a significant risk in publication bias. (Fig. 5, funnel plots).

Adverse events Thirty-five (63.6%) studies reported the occurrence of adverse events (AEs). Among these, 18 (32.7%) [19, 22–24, 28, 29, 37, 38, 41, 44, 47, 49, 53, 56, 59–61, 64, 72] studies stated that no AEs were observed. For the other 17 (30.9%) studies [17, 18, 20, 26, 27, 31, 33, 34, 40, 48, 51, 57, 66, 67, 69, 70, 75], the reported adverse events for the ICWM group mainly included skin discomfort (such as rashes, pruritus, irritation, urticaria, local edema, xerosis) and gastrointestinal disturbance (like nausea, diarrhea, stomach discomfort, abdominal distension, epigastralgia, anorexia, loose stools). Other AEs included feeling of sleepiness, insomnia, dizziness, headache, conjunctivitis, common cold, upper respiratory infection, scabies, right hypochondriac pain, malaise, rhinitis, feverish thirst, dental caries, eosinophilia, GPT elevation, IgE elevation, blood urea nitrogen (BUN) accentuation and serum potassium elevation. Pooled analysis of 19 studies found no significant difference between ICWM and WM groups in the rate of adverse events (RR = 0.91, 95% CI 0.61 to 1.35, participants = 1416, I² = 47%, Fig. 6, effects of ICWM on the rate of adverse events when compared with WM alone).
Fig. 4 Effects of ICWM on the percentage of trial participants with more than 50% improvement in terms of (a) EASI, (b) SCORAD, (c) SASSAD and (d) all other measures when compared with WM alone.
Fig. 4 continued

### (c)

| Study or Subgroup | ICWM Events | Total | WM alone Events | Total | Total Weight | M-H, Random, 95% CI | Risk Ratio | Risk Ratio | Risk of Bias |
|-------------------|-------------|-------|-----------------|-------|--------------|---------------------|------------|------------|--------------|
| Chen 2011         | 15          | 31    | 4               | 30    | 11.5%        | 3.63 [1.35, 9.69]   |            |            |              |
| Chen 2014b        | 19          | 34    | 7               | 30    | 21.7%        | 2.39 [1.17, 4.98]   |            |            |              |
| Shi 2008          | 14          | 25    | 5               | 22    | 15.5%        | 2.46 [1.06, 5.74]   |            |            |              |
| Wang 2014         | 25          | 39    | 12              | 39    | 39.9%        | 2.08 [1.23, 3.53]   |            |            |              |
| Zhang 2005        | 15          | 31    | 4               | 30    | 11.5%        | 3.63 [1.36, 9.69]   |            |            |              |
| Total (95% CI)    | 160         | 151   | 100.0%          |       |              | 2.50 [1.79, 3.49]   |            |            |              |
| Total events      | 88          | 32    |                 |       |              |                     |            |            |              |

Heterogeneity: Tau² = 0.00; Chi² = 1.53, df = 4 (P = 0.80); I² = 0%
Test for overall effect: Z = 5.41 (P < 0.00001)

#### Risk of bias legend
- A: Random sequence generation (selection bias)
- B: Allocation concealment (selection bias)
- C: Blinding of participants and personnel (performance bias)
- D: Blinding of outcome assessment (detection bias)
- E: Incomplete outcome data (attrition bias)
- F: Selective reporting (reporting bias)
- G: Other bias

### (d)

| Study or Subgroup | ICWM Events | Total | WM alone Events | Total | Total Weight | M-H, Random, 95% CI | Risk Ratio | Risk Ratio | Risk of Bias |
|-------------------|-------------|-------|-----------------|-------|--------------|---------------------|------------|------------|--------------|
| Chen 2014a        | 27          | 33    | 8               | 33    | 1.7%         | 3.38 [1.81, 6.30]   |            |            |              |
| Cheng 2012        | 44          | 48    | 36              | 42    | 6.1%         | 1.67 [0.82, 1.24]   |            |            |              |
| Hu 2012           | 30          | 30    | 28              | 30    | 6.5%         | 1.07 [0.98, 1.07]   |            |            |              |
| Huang 2004        | 41          | 49    | 31              | 49    | 4.6%         | 1.32 [1.03, 1.69]   |            |            |              |
| Lai 2017          | 25          | 45    | 18              | 45    | 2.6%         | 1.39 [0.89, 2.16]   |            |            |              |
| Li 2008a          | 31          | 38    | 20              | 38    | 3.7%         | 1.55 [1.11, 2.17]   |            |            |              |
| Li 2008b          | 32          | 44    | 16              | 37    | 3.0%         | 1.68 [1.11, 2.54]   |            |            |              |
| Li 2017           | 17          | 47    | 7               | 31    | 1.4%         | 2.21 [1.06, 4.61]   |            |            |              |
| Li 2018           | 48          | 52    | 27              | 52    | 4.4%         | 1.70 [1.29, 2.25]   |            |            |              |
| Lin 2011          | 24          | 25    | 14              | 25    | 3.5%         | 1.71 [1.20, 2.45]   |            |            |              |
| Liu 2017          | 51          | 60    | 36              | 60    | 5.0%         | 1.42 [1.12, 1.79]   |            |            |              |
| Miao 2014         | 29          | 30    | 21              | 30    | 4.5%         | 1.38 [1.08, 1.78]   |            |            |              |
| Ou 2006           | 25          | 34    | 17              | 30    | 3.4%         | 1.30 [0.89, 1.88]   |            |            |              |
| Song 2017         | 22          | 36    | 11              | 35    | 2.1%         | 1.94 [1.12, 3.39]   |            |            |              |
| Wang 2002         | 634         | 640   | 200             | 270   | 6.6%         | 1.32 [1.23, 1.42]   |            |            |              |
| Wu 2003           | 118         | 118   | 77              | 85    | 6.5%         | 1.11 [1.05, 1.19]   |            |            |              |
| Wu 2014           | 26          | 43    | 8               | 29    | 1.7%         | 2.19 [1.16, 4.15]   |            |            |              |
| Zhang 2012a       | 50          | 60    | 36              | 60    | 5.0%         | 1.39 [1.10, 1.75]   |            |            |              |
| Zhang 2012b       | 18          | 21    | 9               | 21    | 2.2%         | 2.00 [1.18, 3.38]   |            |            |              |
| Zhang 2015        | 41          | 50    | 30              | 50    | 4.6%         | 1.37 [1.05, 1.77]   |            |            |              |
| Zhang 2016        | 47          | 50    | 38              | 50    | 5.6%         | 1.24 [1.04, 1.47]   |            |            |              |
| Zhang 2019        | 27          | 33    | 28              | 30    | 5.6%         | 0.88 [0.73, 1.08]   |            |            |              |
| Zhou 2003         | 28          | 41    | 16              | 32    | 3.1%         | 1.37 [0.91, 2.05]   |            |            |              |
| Zhu 2002          | 28          | 29    | 14              | 17    | 5.6%         | 1.22 [0.87, 1.75]   |            |            |              |
| Total (95% CI)    | 1650        | 1181  | 100.0%          |       |              | 1.35 [1.23, 1.49]   |            |            |              |
| Total events      | 1461        | 746   |                 |       |              |                     |            |            |              |

Heterogeneity: Tau² = 0.03; Chi² = 102.05, df = 23 (P < 0.00001); I² = 77%
Test for overall effect: Z = 6.28 (P < 0.00001)

#### Risk of bias legend
- A: Random sequence generation (selection bias)
- B: Allocation concealment (selection bias)
- C: Blinding of participants and personnel (performance bias)
- D: Blinding of outcome assessment (detection bias)
- E: Incomplete outcome data (attrition bias)
- F: Selective reporting (reporting bias)
- G: Other bias
Discussion

The present research findings suggested that ICWM was superior over WM alone in improving clinical severity of AD (as measured by EASI, SCORAD), health-related quality of life (as measured by CDLQI, DLQI), long term control of AD (recurrence rate), patients/investigator global score (effectiveness rate), and serum IgE level. We found no more adverse events associated with ICWM when compared with WM alone. However, some issues related to study quality weakened the strength of evidence, such as most studies having high risk of bias, conflicting results in some sensitivity analyses and potential publication bias.

The pathogenesis of AD is a complex interplay of multiple contributing factors, such as skin barrier defects, infections, immunological factors, susceptible genes (e.g., filaggrin genes) and environmental factors (e.g., food and aeroallergens, seasonal and climatic change) [7–9]. CM also considers different influencing factors when making syndrome diagnosis of AD, albeit using different terminologies, such as damp-heat accumulation or spleen deficiency. A herbal formula is composed of herbs with different therapeutic functions to exert synergistic therapeutic actions. Experimental studies [78–82] have shown that many bioactive herbal ingredients from CHMs, including Poria (Fuling, 茯苓), Atractylodis Macrocephalae Rhizoma (Baizhu, 白朮), Angelicae Sinensis Radix (Danggui, 当歸), Atractylodis Lancea Rhizoma (Cangzhu, 蒼朮) and Dictamni Cortex (Baixianpi, 白鮮皮), exert anti-inflammatory, anti-allergic, antioxidative, and anti-angiogenic effects. These active ingredients have been demonstrated to attenuate AD through diverse mechanisms such as restoring skin barriers, balancing Th1/Th2 cells levels, as well as regulating cytokine and chemokine expression, while have few side-effects [83, 84].

Fig. 5 Funnel plots for the meta-analysis of a SCORAD, b percentage of trial participants with more than 50% improvement in terms of patients or investigator global score (SCORAD), c percentage of trial participants with more than 50% improvement in terms of patients or investigator global score (all other measures), and d serum IgE level.
The possible interaction between Chinese medicines and WM is one of the serious concerns about clinical safety. In this review, we found no significant difference in the occurrence of AEs between ICWM and WM. Our finding is congruent with previous reports that the combination of ICWM did not evoke additional adverse events [85]. It has also been reported that adding CHMs might have reduced the occurrence of adverse events of conventional pharmacotherapy such as skin dryness, skin itchiness, dry mouth/lips, and dry/scaly skin [86]. Different herbs and pharmacotherapies may be involved in the possible interaction. As CHMs can affect the pharmacokinetic properties of WMs, close attention should be paid to the possible interactions between CHMs and WMs.

To the best of our knowledge, this review is the first of its kind to systematically summarise and analyse the ICWM for AD. The comprehensive search strategy, scientifically robust way to assess risk of bias and the subsequent meta-analysis made the generation of findings more reliable. The low methodological quality and poor reporting are the main problems associated with many included studies which weakened the evidence. No proper blinding is another main methodological problem found in many included studies. As the main outcomes for evaluating the treatment effect for AD are most subjective, the blinding is a very important strategy to reduce possible bias and subjective influences. Additionally, no clear description of random generation and allocation concealment were commonly found in most of the included studies. Further clinical studies with high methodological quality are badly needed to consolidate the evidence about the ICWM for AD management.

Conclusions
Adopting ICWM was found to be superior to using WM alone in improving clinical symptoms and quality of life, and reducing the recurrence rate in the patients with atopic dermatitis. In addition, addition of CHMs to conventional western treatment presented no more adverse effect than WM alone. However, due to the methodological limitations in the included studies and possible publication bias, we could not draw a definitive conclusion about the effectiveness and safety of ICWM for the treatment of AD. In this connection, more methodologically rigorous clinical trials are urgently needed to generate quality clinical evidence about the routine use of ICWM in the management of atopic dermatitis.
1. Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250. https://doi.org/10.1155/2014/354250.

2. Mayba JN, Gooderham MJ. Review of atopic dermatitis and topical therapies. J Cutan Med Surg. 2017;21(3):227–36.

3. Dávıega SP. Epidemiology of atopic dermatitis: a review. Allergy Asthma Proc. 2012;33(3):227–34.

4. Mansouni Y, Guttmann-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858–73.

5. The Hong Kong Allergy Association. Eczema 2014. http://www.allergyhk.org/?page_id=317. Accessed 20 May 2020.

6. Stander S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136–43.

7. Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20(12):74.

8. Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396:345–60.

9. Kapur S, Watson W, Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):S2.

10. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754–65.

11. Gu S, Yang AW, Xue CC, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. Cochrane Database Syst Rev. 2013;9:D8642.

12. Gu SX, Zhang AL, Coyle ME, Chen D, Xue CC. Chinese herbal medicine for atopic eczema: an overview of clinical evidence. J Dermatol Treat. 2017;28(3):246–50.

13. Shi Z, Song T, Xie J, Yan Y, Du Y, Dehym F. The traditional Chinese medicine and relevant treatment for the efficacy and safety of atopic dermatitis: a systematic review and meta-analysis of randomised controlled trials. Evid Based Complement Alternat Med. 2017;2017:6026434. https://doi.org/10.1155/2017/6026434.

14. Brenninkmeijer EE, Schram ME, Leeflang MM, Bos JD, Spuls PI. Diagnostic criteria for atopic dermatitis: a systematic review. Br J Dermatol. 2008;158(4):754–65.

15. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration, 2011. www.handbook.cochrane.org. Accessed Mar 2011.

16. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. https://doi.org/10.1371/journal.pmed.1000100.

17. Gu SX, Mo X, Zhang AL, Liu J, Coyle ME, Ye S, et al. A Chinese herbal medicine preparation (Pei Tu Qing Xin) for children with moderate-to-severe atopic eczema: a pilot randomised controlled trial. Br J Dermatol. 2018;179(6):1404–5.

18. Kobayashi H, Ishii M, Takeuchi S, Tanaka Y, Shintani T, Yamatodani A, et al. Efficacy and safety of a traditional Chinese herbal medicine, Houchu-ekki-toin the long-term management of Kikyo (delicate constitution) patients with atopic dermatitis: a 6-month, multicenter, double-blind, randomised, placebo-controlled study. Evid Based Complement Alternat Med. 2010;7(3):367–73.

19. Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomised, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155(2):141–8.

20. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, base-controlled, multicenter study of 136 patients. Ann Dermatol. 2016;28(5):593–9.

21. Yu T, Chen BJ, Wang P, Zhang YH. Effect of therapy fortifying the spleen and tonifying the kidney on serum total IgE level in patients with atopic dermatitis. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2006;14:S1–5. (In Chinese).

22. Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155(2):141–8.

23. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, base-controlled, multicenter study of 136 patients. Ann Dermatol. 2016;28(5):593–9.

24. Yu T, Chen BJ, Wang P, Zhang YH. Effect of therapy fortifying the spleen and tonifying the kidney on serum total IgE level in patients with atopic dermatitis. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2006;14:S1–5. (In Chinese).

25. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):S8–10.

26. Yamada T, Oka Y, Tahara S, Kato T, Takeuchi H, Kikuchi Y, et al. A randomized trial of a Chinese herbal ingredient as an adjuvant therapy for atopic dermatitis: a double-blind, placebo-controlled trial. J Korean Med Sci. 2012;27(1):117–22.

27. Cheng HM, Chiang LC, Jan YM, Chen GW, Li TC. The efficacy and safety of a Chinese herbal product (Xiao-Feng-San) for the treatment of refractory atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Int Arch Allergy Immunol. 2011;155(2):141–8.

28. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, base-controlled, multicenter study of 136 patients. Ann Dermatol. 2016;28(5):593–9.

29. Yu T, Chen BJ, Wang P, Zhang YH. Effect of therapy fortifying the spleen and tonifying the kidney on serum total IgE level in patients with atopic dermatitis. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2006;14:S1–5. (In Chinese).

30. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, base-controlled, multicenter study of 136 patients. Ann Dermatol. 2016;28(5):593–9.

31. Yu T, Chen BJ, Wang P, Zhang YH. Effect of therapy fortifying the spleen and tonifying the kidney on serum total IgE level in patients with atopic dermatitis. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2006;14:S1–5. (In Chinese).

32. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, base-controlled, multicenter study of 136 patients. Ann Dermatol. 2016;28(5):593–9.

33. Yu T, Chen BJ, Wang P, Zhang YH. Effect of therapy fortifying the spleen and tonifying the kidney on serum total IgE level in patients with atopic dermatitis. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2006;14:S1–5. (In Chinese).

34. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):S8–10.

35. Yamada T, Oka Y, Tahara S, Kato T, Takeuchi H, Kikuchi Y, et al. A randomized trial of a Chinese herbal ingredient as an adjuvant therapy for atopic dermatitis: a double-blind, placebo-controlled trial. J Korean Med Sci. 2012;27(1):117–22.

36. You CE, Moon SH, Lee KH, Kim KH, Park CW, Seo SJ, et al. Effects of emollient containing bee venom on atopic dermatitis: a double-blind, randomised, placebo-controlled study. Hong Kong Med J. 2011;17(Suppl 2):S8–10.
26. Shi H. TCM syndrome characteristics of children with atopic dermatitis and clinical effect of Chinese herbal medicine. Guangming J Chin Med [Guangming Zhong Yi]. 2017;4:468–70 (In Chinese).

27. Zhang YL, Li YW, Lin HE, Tu SZ, Peng J, Liu YI, et al. Clinical efficacy of compound oleum lithospermum combined with loratadine in the treatment of mild to moderate atopic dermatitis. World Chin Med [Shiye Zhong Yi Yao]. 2019;014(6):1511–5 (In Chinese).

28. Yao XY. Clinical observation on treatment of moderate to severe atopic dermatitis with modified spleen strengthening and heart clearing formula and its evaluation of itching improvement. Master thesis. Nanjing University of Chinese Medicine, 2018. (In Chinese).

29. Dong YG, Zhou J. Effect of Jiaqiuxihang combined with hydrocortisone butyrate cream on atopic dermatitis. Guangdong Med J [Guangdong Yi Xue]. 2015;22:3540–2 (In Chinese).

30. Chen BJ, Zhang YH. Observation on the therapeutic effect of Jianpi Lishi decoction on atopic dermatitis and related experimental research. Jilin J Tradit Chin Med [Jilin Zhong Yi Yao]. 2011;1:433–5 (In Chinese).

31. Peng Y, Li B, Li F, Wang YJ, Wu QZ, Chai WH. Clinical effect of Jianpi QuFeng method combined with skin barrier repair milk. Master thesis. Anhui University of Chinese Medicine, 2017. (In Chinese).

32. Peng Y, Li B, Li F, Wang YJ, Wu QZ, Chai WH. Clinical effect of Jianpi QuFeng decoction in treating 95 patients with atopic dermatitis. J Shanghai Univ Tradit Chin Med [Shanghai Zhong Yi Yao Da Xue Xue Bao]. 2015;17(3):45–8 (In Chinese).

33. Huang YJ, Chen DC, Mo XM. Clinical observation of Jianpi Dushi granules in treating children with atopic dermatitis and spleen deficiency syndrome. Shaanxi J Tradit Chin Med [Shaanxi Zhong Yi]. 2004;25(5):396–8 (In Chinese).

34. Lai YQ, Shi XY. Observation on therapeutic effect of fortifying the spleen and draining dampness combined with tacrolimus on atopic dermatitis. Shaanxi J Tradit Chin Med [Shaanxi Zhong Yi]. 2017;38(10):1445–6 (In Chinese).

35. Lin SC. Treatment of spleen deficiency type of atopic dermatitis clinical observation. Master thesis. Guangzhou University of Chinese Medicine, 2011. (In Chinese).

36. Wang JZ, Xi W, Tong XH, Lu C. Detoxification moisturizing decoction in the treatment of atopic dermatitis. Chin J Inf Tradit Chin Med [Zhong Yi Yao Xiu Xi]. 2014;5:111–3 (In Chinese).

37. Chen JH, He XY. Therapeutic effect of Jin Yu Waixi formula on the severity of atopic eczema skin lesions in children— an introduction. Seek Med Ask Med [Qiu Yi Wen Yao]. 2012;11(10):1377–20 (In Chinese).

38. Cheng XC, Yue DR. Observation on the curative effect of Pingweibaohewan granules on infantile eczema. J Sichuan Tradit Chin Med [Sichuan Zhong Yi]. 2012;30(12):100–1 (In Chinese).

39. Chen JH, Fan RQ, Chen XY, Wang X, Xu LP. Clinical study on Jinyu Waixi formula for treatment of dampness-heat atopic eczema in children. J New Chin Med [Xin Zhong Yi]. 2012;44(8):113–5 (In Chinese).

40. Zhang L, Tan XH, Yang L, Ma Y. Effect of Ku Shen tea combined with ultraviolet irradiation on skin barrier function and immune function in patients with atopic dermatitis. ACTA Chin Med [Zhong Yi Yao Xiu Bao]. 2018;33(3):488–91 (In Chinese).

41. Wu BL, Cao Y, Chen LF, Yang XH, Su J, Wei S. Influence of Piyao XiaoJian Decoction II combining with narrow-band UVB exposure on cellular adhesion molecules expression and total IgE level in atopic dermatitis patients. China J Tradit Chin Med Pharm [Zhonghua Zhong Yi Yao Za Zhi]. 2012;27(5):1317–20 (In Chinese).

42. Cheng KC, Yue DR. Observation on the curative effect of Ngweibaohewan granules on infantile eczema. J Sichuan Tradit Chin Med [Sichuan Zhong Yi]. 2012;30(12):100–1 (In Chinese).

43. Chen JH, Fan RQ, Chen XY, Wang X, Xu LP. The effect of self-made Jinyu Waixi formula on the severity of atopic eczema skin lesions in children— an introduction. Seek Med Ask Med [Qiu Yi Wen Yao]. 2012;35:199–20 (In Chinese).

44. Wu DS, Liang Y. A comparative study of adjuvant treatment for atopic dermatitis in infant with natural indigo. Chin J Tradit West Med [Zhong Hua Zhong Yi Yi Ya Zhi]. 2003;4(2):195–6 (In Chinese).

45. Wu DS, Liang Y, Li Y, Xuan HM, Shu HW. A comparative study of adjuvant treatment for atopic dermatitis in infant with natural indigo. Public Med Forum Mag [Ji Ceng Yi Xue Lun Tan]. 2007;11(10):869–70 (In Chinese).

46. Li XZ, Xu P, Pan WD, Zhang HM. Clinical research of Qufeng Lishi mixture in treating fengshi yunfu-type atopic dermatitis. China Med Her [Zhong‑guo Yi Yao Dao Bao]. 2017;14(22):101–4 (In Chinese).

47. Chen QH, Yuan Y. Clinical study on treatment of infantile eczema with external application of Qufang. Chin Manip Rehabil Med [Anmo Yu Kangfu Yi Xue]. 2014;45(5):87–8 (In Chinese).

48. Mao JH, Zhu MF, Zhang XL. Clinical efficacy of pomegranate rind ointment in treatment of atopic dermatitis: a report of 30 cases. Hunan J Tradit Chin Med [Hunan Zhong Yi Za Zhi]. 2014;4(6):24–29 (In Chinese).

49. Ou BS, Liu WB, Wang JM. 34 cases of atopic dermatitis treated by Siwanfeng decoction combined with western medicine. China’s Naturop [Zhongguo Min Jian Liao Fa]. 2006;01:8–9 (In Chinese).

50. Li YY. Observation of curative effect of modified Xiaofeng powder on children with eczema. J Dermatol Venerol [Pfu Bing Yu Xing Bing]. 2018;40(1):109–11 (In Chinese).

51. Yang YH. Study on clinical effect of TCM intervention in treating blood deficiency and wind dryness type atopic dermatitis. Guangming J Chin Med [Guangming Zhong Yi]. 2011;5:4753–5 (In Chinese).

52. Chen BJ. Clinical efficacy of Yinquane Jianpi Runfu method in treating atopic dermatitis and its influences on serum levels of interleukin-18. Chin J Dermatovenerol Integr Tradit West Med [Zhongguo Zhong Yi Yi Ji He Pu Fi Xing Bing Xue Za Zhi]. 2014;5:283–5 (In Chinese).

53. Song XL. Clinical observation on treatment of atopic dermatitis and its influence on IgE by nourishing blood and expelling wind decoction. Heilongjiang Univ Chin Med [Heilongjiang Zhong Yi Yao Da Xue]. 2017. (In Chinese).

54. Xu ZJ. Clinical observation on treatment of 30 cases of atopic dermatitis with Yangxue Runfu decoction and Xiluotuo. Hunan J Tradit Chin Med [Hunan Zhong Yi Za Zhi]. 2018;34(8):77–83 (In Chinese).

55. Liu WJ. Clinical observation on Yupingfeng granules for treatment of infantile atopic dermatitis. J Guangzhou Univ Tradit Chin Med [Guangzhou Zhong Yi Yao Da Xue Xue Bao]. 2019;36(6):800–4 (In Chinese).

56. Xu QJ, Chen S. Clinical observation on children with atopic dermatitis with dampness-heat syndrome treated with integrated traditional Chinese and western medicine. J North Pharm [Bei Fang Yao Xue]. 2017;14(8):9–10 (In Chinese).

57. Yu JS, Wang Q, Li JN. Observation on the therapeutic effect of integrated traditional Chinese and western medicine on children with atopic dermatitis. Chin J Tradit Med Sci Technol [Zhongguo Zhong Yi Yao Ke Ji]. 2016;2:219–20 (In Chinese).

58. Liu Y, Ye QH, Chen JY, He Q, Wang YM, Wei KF. Clinical study on treatment of childhood atopic dermatitis with integrated Chinese and western medicine. J Nanjing TCM Univ [Nanjing Zhong Yi Yao Da Xue Xue Bao]. 2007;2:93–5 (In Chinese).

59. Li F, Luo WH. A summary of 44 cases of atopic dermatitis treated with integrated Chinese and western medicine. Hunan J Tradit Chin Med [Hunan Zhong Yi Za Zhi]. 2006;2(4):20–1 (In Chinese).

60. Wang YS. Clinical observation on atopic dermatitis treated with integrated Chinese and western medicine. China’s Naturop [Zhongguo Min Jian Liao Fa]. 2019;04:73–4 (In Chinese).

61. Shi YJ, Zhang CM, Ma DM, Liu Y, Zhang DY, Zhang CH. Clinical study on treatment of atopic dermatitis by integrated traditional Chinese and western medicine. Chin J Integr Tradit West Med [Zhongguo Zhong Yi Xi Je He Za Zhi]. 2008;28(8):686–8 (In Chinese).

62. Liang Y, Chen BJ. Clinical study of integrated traditional Chinese and western medicine for the treatment of atopic dermatitis. Chin J Dermatovenerol Integr Tradit West Med [Zhongguo Zhong Yi Yi Ji He Pu Fi Xing Bing Xue Za Zhi]. 2005;4(4):207–10 (In Chinese).

63. Hu YS, Zhang BX, Guo YP. Random control study on treating AD in the integrative medicine. Clin J Chin Med [Zhong Yi Lin Chuang Yan Jiu]. 2013;53(3):10–2 (In Chinese).

64. Zhou ZM. Combined TCM and west medicine to treating 41 cases of atopic dermatitis. Huanun Guid JTCMP [Huanun Zhong Yi Yao Dao Bao]. 2003;9(3):34–5 (In Chinese).

65. ZHU CY. Observation of therapeutic effect of integrated Chinese and western medicine on atopic dermatitis. J Modern Med Health [Xianyi Dai Yao Wei Sheng]. 2001;5:368 (In Chinese).

66. Hu NN, Wang XF, Zhao X. Clinical observation on infantile eczema treated with integrated Chinese and western medicine. Liaoning J Tradit Chin Med [Liaoning Zhong Yi Za Zhi]. 2012;39(7):1354–5 (In Chinese).
67. Liu G, Wang Q. Observation on treating AD by TCM medicine umbilical therapy. Clin J Chin Med [Zhong Yi Lin Chuang Yan Jul]. 2017;19:123–4 (In Chinese).
68. Chen JH, Ye GF, Xiu MY. Study on the curative effect of external application of traditional Chinese medicine on 1–6 years old children of spleen deficiency body constitution with atopic dermatitis. Chin Manip Rehabil Med [Anmo Yu Kangfu Yi Xue]. 2018;9(9):44–6 (In Chinese).
69. Han HJ, Guo F, Liu HX. Efficacy and safety observation of Chinese medicine bath joint tacrolimus ointment for the treatment of children with atopic dermatitis. Chin J Dermatovenereal Integr Tradit Med [Zhong‑guo Zhong Yi Yi Ji He Pi Fu Xing Bing Xue Za Zhi]. 2013;12(3):164–6 (In Chinese).
70. Huang WH, Wang CM. Curative effect of TCM medicated bath combined with tacrolimus on moderate to severe atopic dermatitis in children and influence on serum LT84 on LTC4. Chin J Gen Pract [Zhonghua Quan Ke Yi Xue]. 2016;4:60–606 (In Chinese).
71. Wu YB, Qiu GR, Xu LB. Clinical observation on the treatment of 43 cases of atopic dermatitis with TCM syndrome differentiation and claritane. Jiangsu J Tradit Chin Med [Jiangsu Zhong Yi Yao]. 2014;46(6):49–50 (In Chinese).
72. Li WZ. Observation on therapeutic effect of a traditional Chinese medicine empirical formula on atopic dermatitis. Chin Commun Di [Zhong‑guo Shu‑yi Shi]. 2006;8(14):118–9 (In Chinese).
73. Li XJ. Effect of Chinese medicine in treatment of atopic dermatitis. China Health Stand Manaq [Zhongguo Wei Sheng Bao Zhun Guan Li]. 2015;6(19):139–40 (In Chinese).
74. Zhang J. Clinical research of traditional Chinese medicine in the treatment of atopic dermatitis. China J Chin Med [Zhong‑yi Xue Bao]. 2012;27(7):897–8 (In Chinese).
75. Zhou L. The clinical observation of treatment of atopic dermatitis using granules of Ziyin Jianpi decoction. Master thesis. Hubei University of Chinese Medicine. 2012. (In Chinese).
76. Gu SX, Zhang AL, Coyle ME, Mo X, Lenon GB, Cranswick NE, et al. Chinese herbal medicine granules (PTQX) for children with moderate to severe atopic eczema: study protocol for a randomised controlled trial. Trials. 2015;16:1–6.
77. Cheng HM, Chiang LC, Jan YM, Li TC, Chen GW. The efficacy and safety of a Chinese herbal product (Xiao‑Feng‑San) for the treatment of refractory atopic dermatitis: a randomised, double‑blind, placebo‑controlled trial. Eur J Integr Med. 2012;4(SUPPL. 1):69.
78. Cuellar MJ, Giner RM, Recio MC, Just MJ, Mañez S, Rios JL. Effect of the basidiomycete Poria cocos on experimental dermatitis and other inflammatory conditions. Chem Pharm Bull. 1997;45(3):492–4.
79. Kaminaga T, Yasukawa K, Kanno H, Tai T, Nunoura Y, Takido M. Inhibitory effects of lanostane‑type triterpene acids, the components of Poria cocos, on tumor promotion by 12‑O‑tetradecanoylphorbol‑13‑acetate in two‑stage carcinogenesis in mouse skin. Oncology. 1996;53(3):382–5.
80. Prieto JM, Recio MC, Giner RM, Mañez S, Giner‑Larza EM, Rios JL. Influence of traditional Chinese anti‑inflammatory medicinal plants on leukocyte and platelet functions. J Pharm Pharmacol. 2003;55(9):1275–82.
81. Koonrungsomboon N, Na‑Bangchang K, Karbwang J. Therapeutic potential and pharmacological activities of Atractylodes lancea (Thunb.) DC. Asian Pac J Trop Med. 2014;7(6):421–8.
82. Wang XR, Zhou C, Zhong ZD, Duan Q, Du AY, Jing G. Effect of modified Danggui Yinzi on delayed allergy in model mice with Qi‑blood deficiency syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016;36(3):345–7 (In Chinese).
83. Yan F, Li F, Liu J, et al. The formulae and biologically active ingredients of Chinese herbal medicines for the treatment of atopic dermatitis. Biomed Pharmacother. 2020;127:110142.
84. Man MQ, Hu LZ, Elias PM. Herbal medicines prevent the development of atopic dermatitis by multiple mechanisms. Chin J Integr Med. 2019;25(2):151–60.
85. Kim J, Kim H. Combination treatment with herbal medicines and western medicines in atopic dermatitis: benefits and considerations. Chin J Integr Med. 2016;22(5):323–7.
86. Zhang CS, Yu JJ, Parker S, Zhang AL, May B, Lu C, et al. Oral Chinese herbal medicine combined with pharmacotherapy for psoriasis vulgaris: a systematic review. Int J Dermatol. 2014;53(11):1305–18.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.